Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Let them short, they will be grilled..
Shares are almost sold out, that will bring huge hikes in pp soon..
PP back to $6.00 so It was not long ago..
Hold an buy more..
Shorts wil get burned hard..
Gltya
Hope so.. then skyrocket $$ITRM
Here we gooooooo $$
You should have hold a part.. imo
Glty.. you will be back soon.. ;)
ITRM could be a goldmine
We have a bid at $1 lol..
Here we gooooo... playtime on low volume is over lol.
Could see 1 dollar soon.
Did you see big 159k on 0.95 ;)
I still buy more, this will run hard imo on big buys, at open today +300k it openend @.95
So I have the time to wait and see this dubble/triple soon..Yes they want this approved.. Me to lol
Gltya.. ;)
Currently is authorized to issue 150m ordinary shares and 100m preferred shares. Par values is $0.01, which doesn't really mean anything, but that's where you get the $2.5m share capital value. In essence, two of the votes will effectively increase their authorized ordinary shares to 300m. The reason for this, is even though outstanding shares was last reported as 43m, they have over 102m more currently reserved between outstanding convertible notes, warrants, and employee stock options. So per the filing, they actually have less than 5m authorized shares that they can work with. Yes, this is to allow them flexibility to issue more shares in the future. But that's pretty standard to keep a good cushion for that. I would recommend voting for the proposal, because the alternative route of achieving the same thing is an R/S. And the convertible notes have crazy terms if the company defaults.
Copy/past from Stockroket1 on another side I think he explaned it right.. thx
ITRM we are ready for news.!!
Bought more even @ 0.90 ;)
Buy,buy grill the shorts here.. NVCN has 6 months to compl.with Nasdaq 1 dollar bid.
I agree..we dont have to wait that long..
lol ;)
ITRM has now marketcap just about a low 40 mil.
$$$$
If we get an dayvolume above 50 mil. I think we can see $3 monday at lunchtime..
Gltya,..
Low float, on the big positions in ITRM. BIG news expected soon...
https://alphastocknews.com/iterum-therapeutics-itrm-stock-rockets-as-big-money-jumps-in/4891/
Float soon sold out!!
Here we go... kaboooooom!! Next stop $8,10,12 and more next weeks
They shake weak hands out. I bought more on this dip.. ITRM is ready to rock..
And me to... gltya
News out.. Iterum Therapeutics Announces Filing of US Patent Application Based on Favorable Written Opinion of the International Search ...
December 07 2020 - 08:00AM
GlobeNewswire Inc.
Alert
Print
Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced the filing of a U.S. national phase patent application directed to the composition of the bilayer tablet of sulopenem etzadroxil and probenecid and its related uses with the U.S. Patent and Trademark Office (“USPTO”).
“If approved, this U.S. patent application related to the bilayer tablet, which includes both sulopenem etzadroxil as well as probenecid, could provide U.S. patent coverage for Iterum’s commercial formulation out to 2039, excluding any additional term for patent term adjustment or patent term extension, thereby extending the current patent protection afforded by the existing sulopenem etzadroxil patent estate,” said Corey Fishman, Chief Executive Officer. “We are encouraged by the Written Opinion of the International Search Authority, which indicates that several claims directed to the composition of the tablet are novel and inventive. We anticipate additional patent filings in countries outside the U.S., including Europe and China, which should help facilitate partnering discussions in those regions.”
The sulopenem bilayer tablet contains sulopenem etzadroxil, a prodrug of sulopenem that enables oral bioavailability, and probenecid, a renal tubular transport blocking agent, which together enhance the exposure of sulopenem to the bacterial pathogen responsible for the infection. These claims encompass the oral formulation used in the Phase 3 registration studies to support the safety and efficacy of sulopenem etzadroxil and probenecid. An extension of the life of the patent estate would enable pursuit of claims related to our previously granted QIDP indications such as pneumonia.
Take-over candidate when big investors take position in ITRM reed SEC fillings $$$
$ITRM ready for next level up!!
Back to $7 gogooo
Breakout !! $gril
It will, could dubble in pp soon.
Today conf.call
Shorts will get a hard time today..
;) gltya
Here we goooo.. $$
Explosion soon..gltya
U. S. Well Services Announces Third Quarter 2020 Earnings Release Date and Conference Call
Tue, October 20, 2020, 10:15 PM GMT+2·2 mins read
USWS
-0.61%
HOUSTON, Oct. 20, 2020 /PRNewswire/ -- U. S. Well Services, Inc. (NASDAQ: USWS) will issue its financial and operating results for the third quarter 2020 after the market closes on Thursday, November 5, 2020 and host its earnings conference call and webcast at 10:00 a.m. Central Time on Friday, November 6, 2020.
By Phone:
Dial 201-389-0872 approximately 10 minutes before the call and ask for the U.S. Well Services call.
By Webcast:
Log onto U.S. Well Services' website to access an audio webcast, which can be found in the Investor Relations section under "Events & Presentations" tab at http://ir.uswellservices.com/events-and-presentations/events.
For those who cannot listen to the live call, a replay will be available through November 13 and may be accessed by dialing 201-612-7415 and using the passcode 13712348#. Also, an archive of the webcast will be available shortly after the call at http://ir.uswellservices.com/events-and-presentations/events.
0.58 on the board..
Nxtd next jump has started..
They trying to steel from week hands...
Brokerage firms currently have a positive stance on shares of Akers Biosciences, Inc. (NASDAQ:AKER). The majority of analysts covering the equity have either a Buy or Strong Buy recommendation on the stock, yielding a consensus score of 2.00. Those same analysts are projecting that the stock will reach $4.00 on a short term basis.
http://alphabetastock.com/2018/02/05/hot-stocks-alert-akers-biosciences-inc-nasdaq-aker-2/
Vemanti Group Announces Investment In TrustPay, A Blockchain-Focused Fintech Company
By GlobeNewswire, January 30, 2018, 08:30:00 AM EDT
Vote up
AAA
NEWPORT BEACH, Calif., Jan. 30, 2018 (GLOBE NEWSWIRE) -- Vemanti Group, Inc. (OTC PINK:VMNT), a technology-driven holding company, today announced that it has entered into an agreement to take 19.6% interest in TrustPay USA, Inc. ("TrustPay"), an innovative blockchain-focused FinTech company.
TrustPay is the parent company of TrustPay, JSC, a B2B, B2C, and P2P financial services, merchant services aggregator, and mobile payment company with operations based in Ho Chi Minh City, Vietnam. In partnership with 22 leading national banks, the company develops and markets several software and hardware payments products, including mobile apps, digital gateways, cloud-based POS, QR readers, virtual prepaid VISA cards, and NFC/HCE applications. In the last 5 years, it has focused product development efforts on 2 key blockchain-based financial applications: an AI-driven digital banking platform and a cryptocurrency trading exchange, TrustDex (www.trustdex.io).
The investment agreement follows a successful pilot program of TrustDex in early December 2017 managed by TrustPay and the Company, offering consumers based in the countries of South East Asia improved access to online cryptocurrency trading. The pilot program attracted more than 10,000 trades per day within 3 weeks. As part of the deal, the Company and TrustPay agree on a partnership to expand global and US market presence for TrustDex and to bring innovative digital currency-based financial services to underbanked markets around the world. TrustPay is working on an API integration to Coinbase (www.coinbase.com), one of the world's biggest exchanges, for Bitcoin, Bitcoin Cash, Litecoin, and Ethereum transactions. It's also looking to launch its Banking-as-a-Service (BaaS) offering and deliver its unique AI and machine-learning technology to 500,000-strong network of merchants and users.
"Our goal is to build up assets and valuation. Obviously, we are very pleased to add this FinTech investment to our portfolio. With a target regional market of over 640 million people and 2.6 trillion in GDP to start, we expect TrustDex alone to have tremendous financial achievements this year. And with an experienced blockchain engineering team already on-board, we'll also be able to help accelerate TrustPay's product launch roadmap for their digital banking platform," stated Tan Tran, CEO of Vemanti Group.
"We're excited to welcome Vemanti into TrustPay," explains Eric Vuong, Chairman and CEO for TrustPay. "We don't take on a new investor unless we feel that they also bring a positive impact to our business. Just in a few months of working together, we have come to greatly appreciate the astute approach to business by Vemanti. They are the right investor and partner for the next phase of our growth. The global opportunity within the blockchain-based financial sector broadly has far more potential than we can practically execute ourselves. With Vemanti, we now have the partnership we want and need to scale."
As part of the agreement, the Company will execute an equity exchange for 19.6% percent interest in TrustPay initially with options to increase its stake later. Once finalized, details of the transaction will be included the Company's filings.
About Vemanti Group, Inc.
Vemanti Group, Inc. (OTC PINK:VMNT) is a technology-driven holding company that seeks to be active in high-growth and emerging markets. Our core strengths are in technology development and investment. We plan to grow through acquisition and investment in disruptive and foundational technologies by targeting early-stage businesses that have market viable products or by starting a new subsidiary of our own. Strategically, we focus mainly on early-stage Fintech and E-commerce companies based on blockchain technology. For more information, please follow: http://www.vemanti.com
About TrustPay USA, Inc.
TrustPay USA, Inc. is the parent company of TrustPay, JSC (www.trustpay.vn), a B2B, B2C, and P2P financial services, merchant services aggregator, and mobile payment company with operations based in Ho Chi Minh City, Vietnam which started in 2009. TrustPay, JSC also owns TrustCard (www.trustcard.vn), a digital prepaid VISA/MasterCard card issuer, TrustWorld (www.trustworld.vn), a digital loyalty and group-buying platform, and TrustShop (www.trustshop.vn), an online e-commerce platform. It also has holdings in various fintech startups in Vietnam and with office locations in the UK, Singapore, and Cambodia. In partnership with 22 national banks, the company markets several software and hardware payments products. It's currently focusing on blockchain and cryptocurrency applications.
Legal Disclaimer
This release contains forward-looking statements within the meaning of Section 27a of the Securities Act of 1933, as amended and section 21e of the Securities and Exchange Act of 1934, as amended. Those statements include the intent, belief or current expectations of the company and its management team. Forward-looking statements are projections of events, revenues, income, future economics, research, development, reformulation, product performance or management's plans and objectives for future operations. Some or all of the events or results anticipated by these forward-looking statements may not occur. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. Accomplishing the strategy described herein is significantly dependent upon numerous factors, many that are not in management's control.
Contact Information Vemanti Group, Inc. Investor Relations (800) 768-1288 ir@vemanti.com
Source: Vemanti Group, Inc
This article appears in: News Headlines
Referenced Stocks: VMNT
Nice point to buy more..
Prise up before the news release ??
Breakout!! Up to .....
Goooo FORD
They tryed to shake out weak hands for the big run up.. ;)
Shorts cover and hold till........
Goooo FORD
Low float $$$